n-methyl-3,4-methylenedioxyamphetamine has been researched along with Anxiety in 71 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
Excerpt | Relevance | Reference |
---|---|---|
"PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca." | 5.41 | Psychedelics for Patients With Cancer: A Comprehensive Literature Review. ( Dalo, J; Weisman, N; White, CM, 2023) |
"Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 5.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
" Our experiments were designed to examine the effects of a concomitant administration of 3,4-methylenedioxy-methamphetamine (MDMA) and mephedrone on depression- and anxiety-like behaviors and cognitive processes in Swiss mice." | 3.85 | Acute behavioral effects of co-administration of mephedrone and MDMA in mice. ( Biała, G; Budzynska, B; Frankowska, M; Kaszubska, K; Michalak, A, 2017) |
" The possibility that some of these psychological problems are caused by ecstasy-induced neurotoxicity is supported by preclinical evidence of MDMA-induced neurotoxicity and behavioural deficits, evidence of depleted serotonin in heavy ecstasy users, and by dose-response relationships between the extent of exposure to ecstasy and the severity of cognitive impairments." | 2.41 | Ecstasy (MDMA): a review of its possible persistent psychological effects. ( Morgan, MJ, 2000) |
"Despite its efficacy in PTSD and anxiety, MDMA did not reduce either the subjective or objective responses to stress in this controlled study." | 1.46 | MDMA does not alter responses to the Trier Social Stress Test in humans. ( Bershad, AK; de Wit, H; Miller, MA, 2017) |
"The dependent variable was the number of reported ecstasy-related adverse effects." | 1.37 | Modelling the adverse effects associated with ecstasy use. ( Fisk, JE; Hadjiefthyvoulou, F; Montgomery, C; Murphy, PN, 2011) |
" Locomotor activity and body weight were assessed during the dosing period and withdrawal-related anxiety was assessed 24 h after drug cessation." | 1.36 | Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. ( Arnold, JC; Hunt, GE; Long, LE; McGregor, IS; van Nieuwenhuijzen, PS, 2010) |
" Regardless of dosing regimen, MDMA treatment produced path integration deficits as evidenced by an increase in latency to find the goal in the Cincinnati water maze." | 1.35 | (+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks. ( Able, JA; Grace, CE; Gudelsky, GA; Herring, NR; Schaefer, TL; Skelton, MR; Vorhees, CV; Williams, MT, 2008) |
" However, such dosing regimens do not adequately mimic the intermittent use patterns commonly seen in adolescent recreational ecstasy users." | 1.35 | Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. ( Meyer, JS; Piper, BJ; Vancollie, VE, 2008) |
"In recent work we have documented lasting adverse neurochemical and behavioural effects in rats given short-term 'binge' dosing with methylenedioxymethamphetamine (MDMA, Ecstasy), methamphetamine (METH) or their combination." | 1.34 | Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. ( Clemens, KJ; Cornish, JL; Hunt, GE; McGregor, IS, 2007) |
"These results indicate that hyperthermia at the time of dosing with MDMA is not necessary to produce subsequent 5-HT depletion and anxiety in rats." | 1.32 | Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. ( Blokland, A; Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Morley, KC, 2003) |
"Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 1.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (4.23) | 18.2507 |
2000's | 38 (53.52) | 29.6817 |
2010's | 28 (39.44) | 24.3611 |
2020's | 2 (2.82) | 2.80 |
Authors | Studies |
---|---|
White, CM | 1 |
Weisman, N | 1 |
Dalo, J | 1 |
Wolfson, PE | 1 |
Andries, J | 1 |
Feduccia, AA | 2 |
Jerome, L | 2 |
Wang, JB | 1 |
Williams, E | 1 |
Carlin, SC | 1 |
Sola, E | 1 |
Hamilton, S | 1 |
Yazar-Klosinski, B | 2 |
Emerson, A | 2 |
Mithoefer, MC | 1 |
Doblin, R | 1 |
Bershad, AK | 1 |
Miller, MA | 1 |
de Wit, H | 1 |
Danforth, AL | 1 |
Grob, CS | 1 |
Struble, C | 1 |
Walker, N | 1 |
Scott, RM | 3 |
Hides, L | 3 |
Allen, JS | 3 |
Lubman, DI | 3 |
Wetherell, MA | 1 |
Montgomery, C | 2 |
Montagud-Romero, S | 1 |
Daza-Losada, M | 1 |
Vidal-Infer, A | 2 |
Maldonado, C | 3 |
Aguilar, MA | 3 |
Miñarro, J | 4 |
Rodríguez-Arias, M | 4 |
García-Pardo, MP | 1 |
Manzanedo, C | 1 |
Karimi, S | 1 |
Jahanshahi, M | 1 |
Golalipour, MJ | 1 |
Ramos, L | 1 |
Hicks, C | 1 |
Caminer, A | 1 |
Goodwin, J | 1 |
McGregor, IS | 11 |
Fulde, GW | 1 |
Forster, SL | 1 |
Johansson, EM | 1 |
García-Gutiérrez, MS | 1 |
Moscoso-Castro, M | 1 |
Manzanares, J | 1 |
Valverde, O | 4 |
Macúchová, E | 1 |
Ševčíková, M | 1 |
Hrebíčková, I | 1 |
Nohejlová, K | 1 |
Šlamberová, R | 1 |
Jones, L | 1 |
Reed, P | 1 |
Parrott, A | 1 |
Ponzoni, L | 1 |
Sala, M | 1 |
Braida, D | 1 |
Budzynska, B | 1 |
Michalak, A | 1 |
Frankowska, M | 1 |
Kaszubska, K | 1 |
Biała, G | 1 |
Hasler, F | 1 |
Studerus, E | 1 |
Lindner, K | 1 |
Ludewig, S | 1 |
Vollenweider, FX | 3 |
Skelton, MR | 2 |
Able, JA | 1 |
Grace, CE | 2 |
Herring, NR | 2 |
Schaefer, TL | 2 |
Gudelsky, GA | 1 |
Vorhees, CV | 2 |
Williams, MT | 2 |
Bedi, G | 1 |
Van Dam, NT | 1 |
Redman, J | 1 |
Meyer, JS | 2 |
Piper, BJ | 2 |
Vancollie, VE | 1 |
Adori, C | 2 |
Zelena, D | 1 |
Tímár, J | 1 |
Gyarmati, Z | 1 |
Domokos, A | 1 |
Sobor, M | 1 |
Fürst, Z | 1 |
Makara, G | 1 |
Bagdy, G | 3 |
Andó, RD | 2 |
Kirilly, E | 2 |
Molnár, E | 1 |
Kovács, GG | 1 |
Ferrington, L | 2 |
Kelly, PA | 2 |
Burke, R | 1 |
van Nieuwenhuijzen, PS | 1 |
Long, LE | 1 |
Hunt, GE | 8 |
Arnold, JC | 1 |
Fisk, JE | 1 |
Murphy, PN | 1 |
Hadjiefthyvoulou, F | 1 |
Ruiz-Medina, J | 3 |
Ledent, C | 1 |
Carretón, O | 1 |
Ferraz-de-Paula, V | 1 |
Stankevicius, D | 1 |
Ribeiro, A | 1 |
Pinheiro, ML | 1 |
Rodrigues-Costa, EC | 1 |
Florio, JC | 1 |
Lapachinske, SF | 1 |
Moreau, RL | 1 |
Palermo-Neto, J | 1 |
Guerri, C | 1 |
Ros-Simó, C | 1 |
Hare, BD | 1 |
D'Onfro, KC | 1 |
Hammack, SE | 1 |
Falls, WA | 1 |
Pinto-Xavier, A | 1 |
Kolyaduke, OV | 1 |
Hughes, RN | 1 |
Green, AR | 1 |
Parrott, AC | 1 |
Buchanan, T | 1 |
Scholey, AB | 1 |
Heffernan, T | 1 |
Ling, J | 1 |
Rodgers, J | 1 |
Navarro, JF | 2 |
Maldonado, E | 2 |
Clemens, KJ | 5 |
Van der Plasse, G | 1 |
Li, KM | 5 |
Chen, F | 1 |
Lawrence, AJ | 1 |
Gurtman, CG | 3 |
Morley, KC | 4 |
Blokland, A | 1 |
Cornish, JL | 4 |
Thompson, MR | 1 |
Verheyden, SL | 1 |
Maidment, R | 1 |
Curran, HV | 2 |
Van Nieuwenhuyzen, PS | 1 |
Sumnall, HR | 1 |
O'Shea, E | 1 |
Marsden, CA | 1 |
Cole, JC | 1 |
Ho, YJ | 1 |
Pawlak, CR | 1 |
Guo, L | 1 |
Schwarting, RK | 2 |
Check, E | 1 |
De Almeida, SP | 1 |
Silva, MT | 1 |
Mejias, S | 1 |
Rossignol, M | 1 |
Debatisse, D | 1 |
Streel, E | 1 |
Servais, L | 1 |
Guérit, JM | 1 |
Philippot, P | 1 |
Campanella, S | 1 |
Palenicek, T | 1 |
Votava, M | 1 |
Bubenikova, V | 1 |
Horacek, J | 1 |
Uys, JD | 1 |
Niesink, RJ | 1 |
Benko, A | 1 |
Hoshi, R | 1 |
Pratt, H | 1 |
Mehta, S | 1 |
Bond, AJ | 1 |
Lamers, CT | 1 |
Bechara, A | 1 |
Rizzo, M | 1 |
Ramaekers, JG | 1 |
Baumann, MH | 1 |
Wang, X | 1 |
Rothman, RB | 1 |
Walker, QD | 1 |
Williams, CN | 1 |
Jotwani, RP | 1 |
Waller, ST | 1 |
Francis, R | 1 |
Kuhn, CM | 1 |
Medina, KL | 1 |
Shear, PK | 1 |
Reid, LW | 1 |
Elifson, KW | 1 |
Sterk, CE | 1 |
Alati, R | 1 |
Kinner, SA | 1 |
Hayatbakhsh, MR | 1 |
Mamun, AA | 1 |
Najman, JM | 1 |
Williams, GM | 1 |
Ludwig, V | 1 |
Mihov, Y | 1 |
Cohen, RS | 1 |
Lin, HQ | 1 |
Burden, PM | 1 |
Christie, MJ | 1 |
Johnston, GA | 1 |
McCann, UD | 1 |
Eligulashvili, V | 1 |
Mertl, M | 1 |
Murphy, DL | 1 |
Ricaurte, GA | 1 |
Gamma, A | 1 |
Frei, E | 1 |
Lehmann, D | 1 |
Pascual-Marqui, RD | 1 |
Hell, D | 1 |
Liechti, ME | 1 |
Morgan, MJ | 1 |
Gallate, JE | 1 |
Mallet, PE | 1 |
Mechan, AO | 1 |
Moran, PM | 1 |
Elliott, M | 1 |
Young, AJ | 1 |
Joseph, MH | 1 |
Green, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness[NCT02427568] | Phase 2 | 18 participants (Actual) | Interventional | 2015-05-14 | Completed | ||
Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults[NCT02008396] | Phase 2 | 12 participants (Actual) | Interventional | 2014-04-11 | Completed | ||
Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI): A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder[NCT05138068] | Phase 2 | 90 participants (Actual) | Interventional | 2022-04-13 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: 3 months post-enrollment
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | 57.4 |
MDMA-assisted Therapy (125 mg) | 62.5 |
The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -14.6 |
MDMA-assisted Therapy (125 mg) | -20.9 |
The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | 3.0 |
MDMA-assisted Therapy (125 mg) | 6.6 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, > 34 severe depression. Higher scores indicate greater severe depression. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -7.0 |
MDMA-assisted Therapy (125 mg) | -10.5 |
The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -0.2 |
MDMA-assisted Therapy (125 mg) | -3.6 |
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -2.6 |
MDMA-assisted Therapy (125 mg) | 12.9 |
"The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 almost never to 5 almost always. The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses.~A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -0.04 |
MDMA-assisted Therapy (125 mg) | 0.4 |
"The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -6.0 |
MDMA-assisted Therapy (125 mg) | -22.1 |
"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | -8.8 |
MDMA-assisted Therapy (125 mg) | -23.5 |
"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: One month post-2nd experimental session
Intervention | score on a scale (Mean) |
---|---|
Placebo With Therapy | 48.6 |
MDMA-assisted Therapy (125 mg) | 38.9 |
"The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from strongly disagree (score of 1) to strongly agree (score of 7), with higher scores indicating more positive attitudes toward death.~The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
Fear of death | Death avoidance | Neutral acceptance | Approach acceptance | Escape acceptance | |
MDMA-assisted Therapy (125 mg) | -0.1 | 0 | 0.1 | 0.3 | 0.4 |
Placebo With Therapy | -0.6 | -1.1 | 0.2 | -0.1 | 0 |
The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
Physical well-being | Social/ family well-being | Emotional well-being | Functional well-being | Additional concerns | |
MDMA-assisted Therapy (125 mg) | 1.4 | 0.8 | 1.6 | 4.8 | 4.5 |
Placebo With Therapy | 2.8 | -2.0 | 1.0 | 1.0 | -0.3 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline to 1-Month Post Experimental Session 2
Intervention | score on a scale (Mean) |
---|---|
Inactive Placebo With Psychotherapy | -19.3 |
75 mg to 125 mg MDMA With Psychotherapy | -44.1 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: 1-Month Post Experimental Session 2
Intervention | score on a scale (Mean) |
---|---|
Inactive Placebo With Psychotherapy | 64.0 |
75 mg to 125 mg MDMA With Psychotherapy | 46.4 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline
Intervention | score on a scale (Mean) |
---|---|
Inactive Placebo With Psychotherapy | 83.3 |
75 mg to 125 mg MDMA With Psychotherapy | 91.8 |
5 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety
Article | Year |
---|---|
Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
Topics: Antidepressive Agents; Anxiety; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Neopl | 2023 |
The impact of amphetamine-type stimulants on emergency services.
Topics: Acute Disease; Aggression; Amphetamine; Amphetamine-Related Disorders; Anxiety; Central Nervous Syst | 2015 |
Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
Topics: Anxiety; Body Temperature; Depression; Dopamine; Hallucinogens; Humans; Hydroxybutyrates; N-Methyl-3 | 2005 |
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.
Topics: Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Brain; Dopamine; Dose-Response Relationship | 2007 |
Ecstasy (MDMA): a review of its possible persistent psychological effects.
Topics: Affect; Aggression; Animals; Anxiety; Brain; Cognition Disorders; Humans; Memory; N-Methyl-3,4-methy | 2000 |
8 trials available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety
Article | Year |
---|---|
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2020 |
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2020 |
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2020 |
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2020 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum | 2018 |
Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA.
Topics: Adult; Affect; Anxiety; Cognition; Double-Blind Method; Humans; Male; N-Methyl-3,4-methylenedioxyamp | 2009 |
An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?
Topics: Adult; Affect; Aggression; Alcoholic Intoxication; Amphetamine-Related Disorders; Anxiety; Attention | 2006 |
Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.
Topics: Adult; Amphetamine-Related Disorders; Anxiety; Cognition Disorders; Decision Making; Depression; Dis | 2006 |
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
Topics: Adult; Affect; Anxiety; Behavior; Female; Hallucinogens; Humans; Hydrocortisone; Male; N-Methyl-3,4- | 1999 |
Mood state and brain electric activity in ecstasy users.
Topics: Adult; Affect; Anxiety; Electroencephalography; Female; Hallucinogens; Humans; Male; N-Methyl-3,4-me | 2000 |
Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
Topics: Adult; Affect; Antipsychotic Agents; Anxiety; Blood Pressure; Body Temperature; Consciousness; Dopam | 2000 |
58 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety
Article | Year |
---|---|
MDMA does not alter responses to the Trier Social Stress Test in humans.
Topics: Anxiety; Blood Pressure; Central Nervous System Stimulants; Exercise Test; Hallucinogens; Heart Rate | 2017 |
Coping style and ecstasy use motives as predictors of current mood symptoms in ecstasy users.
Topics: Adaptation, Psychological; Adolescent; Adult; Affective Symptoms; Anxiety; Australia; Child; Cross-S | 2013 |
Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.
Topics: Anxiety; Case-Control Studies; Circadian Rhythm; Depression; Drug Users; Female; Humans; Hydrocortis | 2014 |
The novelty-seeking phenotype modulates the long-lasting effects of intermittent ethanol administration during adolescence.
Topics: Adolescent; Aging; Animals; Anxiety; Behavior, Animal; Cocaine; Ethanol; Exploratory Behavior; Human | 2014 |
Effects of acute social stress on the conditioned place preference induced by MDMA in adolescent and adult mice.
Topics: Aging; Animals; Anxiety; Conditioning, Psychological; Corticosterone; Dominance-Subordination; Dose- | 2014 |
The effect of MDMA-induced anxiety on neuronal apoptosis in adult male rats' hippocampus.
Topics: Animals; Anxiety; Apoptosis; Behavior, Animal; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Cel | 2014 |
Oxytocin and MDMA ('Ecstasy') enhance social reward in rats.
Topics: Animals; Anxiety; Arginine Vasopressin; Conditioning, Operant; Dose-Response Relationship, Drug; Mal | 2015 |
Reduced Contextual Discrimination following Alcohol Consumption or MDMA Administration in Mice.
Topics: Alcohol Drinking; Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; | 2015 |
How various drugs affect anxiety-related behavior in male and female rats prenatally exposed to methamphetamine.
Topics: Analgesics; Analysis of Variance; Animals; Anxiety; Central Nervous System Stimulants; Estrous Cycle | 2016 |
Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users.
Topics: Adult; Anger; Anxiety; Cross-Sectional Studies; Female; Humans; Illicit Drugs; Male; Methamphetamine | 2016 |
Ritanserin-sensitive receptors modulate the prosocial and the anxiolytic effect of MDMA derivatives, DOB and PMA, in zebrafish.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Hallucinogens; Motor Activity; N-Methyl-3,4 | 2016 |
Acute behavioral effects of co-administration of mephedrone and MDMA in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Cognition; Depression; Disease Models, Animal; Drug Interac | 2017 |
(+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks.
Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Body Weight; Hallucinogens; Learning; Male; Ma | 2008 |
Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
Topics: Adolescent; Adult; Anxiety; Depression; Female; Hallucinogens; Humans; Male; Marijuana Abuse; Multiv | 2010 |
Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Animals; Anxiety; Behavior, Animal; Body Temperatu | 2008 |
Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.
Topics: Aging; Animals; Anxiety; Body Weight; Cues; Female; Hallucinogens; Learning; Lighting; Maze Learning | 2009 |
Intermittent prenatal MDMA exposure alters physiological but not mood related parameters in adult rat offspring.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Blood Glucose; Body Weight; Corpus | 2010 |
Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion.
Topics: Animals; Anxiety; Axons; Brain; Citalopram; Fluoxetine; Male; N-Methyl-3,4-methylenedioxyamphetamine | 2010 |
Depressive and anxiety symptomatology in ecstasy users: the relative contribution of genes, trauma, life stress and drug use.
Topics: Adolescent; Adult; Affect; Anxiety; Depression; Female; Hallucinogens; Humans; Male; N-Methyl-3,4-me | 2010 |
Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.
Topics: Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Body Weight; Brain; Chromatography, High Pr | 2010 |
Modelling the adverse effects associated with ecstasy use.
Topics: Affect; Alcohol Drinking; Anxiety; Binomial Distribution; Confusion; Dose-Response Relationship, Dru | 2011 |
The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA.
Topics: Animals; Anxiety; Astrocytes; Behavior, Animal; Body Temperature; Central Nervous System Stimulants; | 2011 |
Differential behavioral outcomes of 3,4-methylenedioxymethamphetamine (MDMA-ecstasy) in anxiety-like responses in mice.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Corticosterone; Exploratory Behavior; Fear; Hal | 2011 |
Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.
Topics: Age Factors; Animals; Anxiety; Behavior, Animal; Brain; Dopamine; Dose-Response Relationship, Drug; | 2011 |
Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice.
Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Drug Interactions; Ethanol; Hallucinogens; Inf | 2012 |
Subacute effects of ecstasy on mood: an exploration of associated risk factors.
Topics: Adult; Affect; Anxiety; Depression; Female; Follow-Up Studies; Humans; Male; Mental Disorders; N-Met | 2013 |
Prior stress interferes with the anxiolytic effect of exercise in C57BL/6J mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Fever; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Meth | 2012 |
Influence of chronic caffeine on MDMA-induced behavioral and neuroinflammatory response in mice.
Topics: Animals; Anxiety; Astrocytes; Behavior, Animal; Body Temperature; Caffeine; Central Nervous System S | 2013 |
Increased anxiety-related behavior in male and female adult rats following early and late adolescent exposure to 3,4-methylenedioxymethamphetamine (MDMA).
Topics: Age Factors; Aging; Animals; Anxiety; Female; Male; Maze Learning; N-Methyl-3,4-methylenedioxyamphet | 2013 |
On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Brain Chemistry; Cerebral Cortex; Maze Lear | 2002 |
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
Topics: Anxiety; Depression; Humans; Illicit Drugs; Internet; Memory Disorders; N-Methyl-3,4-methylenedioxya | 2002 |
Acute and subchronic effects of MDMA ("ecstasy") on anxiety in male mice tested in the elevated plus-maze.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Dose-Response Relationship, Drug; Drug Toler | 2002 |
Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density.
Topics: Animals; Anxiety; Carrier Proteins; Male; Membrane Glycoproteins; Membrane Transport Proteins; N-Met | 2003 |
Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes.
Topics: Amygdala; Animals; Anxiety; Biogenic Monoamines; Cognition; Corpus Striatum; Depression; Fever; Hipp | 2003 |
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Fluids; Body Temperature; Body Weig | 2004 |
Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
Topics: Adult; Affect; Aggression; Amphetamine-Related Disorders; Anxiety; Decision Making; Hallucinogens; H | 2003 |
MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat.
Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Corpus Striatum; Dopamine; Dopamine Agents; Dr | 2004 |
The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test.
Topics: Animals; Anxiety; Drug Interactions; Hippocampus; Illicit Drugs; Male; Maze Learning; N-Methyl-3,4-m | 2004 |
Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat.
Topics: Analysis of Variance; Animals; Anxiety; Avoidance Learning; Body Temperature; Dose-Response Relation | 2004 |
Psychedelic drugs: the ups and downs of ecstasy.
Topics: Agaricales; Animals; Anxiety; Brain; Cactaceae; Controlled Clinical Trials as Topic; Female; Halluci | 2004 |
Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period.
Topics: Age Factors; Animals; Anxiety; Male; Membrane Glycoproteins; Membrane Transport Proteins; Memory Dis | 2004 |
Characteristics of ecstasy users in Sãio Paulo, Brazil.
Topics: Adult; Anxiety; Brazil; Catchment Area, Health; Depression; Disruptive, Impulse Control, and Conduct | 2005 |
Event-related potentials (ERPs) in ecstasy (MDMA) users during a visual oddball task.
Topics: Adult; Anxiety; Attention; Discrimination, Psychological; Electroencephalography; Evoked Potentials; | 2005 |
Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats.
Topics: Animals; Anxiety; Behavior, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Female; | 2005 |
Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Male; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; | 2006 |
Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Brain Chemistry; Drug Interactions; Methamphetamine; N-Me | 2007 |
Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats.
Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Brain; Female; Hallucinogens; Hydroxyindoleace | 2007 |
Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.
Topics: Affect; Anxiety; Behavioral Symptoms; Depression; Female; Humans; Male; N-Methyl-3,4-methylenedioxya | 2007 |
Hug drug or thug drug? Ecstasy use and aggressive behavior.
Topics: Adult; Affect; Aggression; Amphetamine-Related Disorders; Anxiety; Attention; Concept Formation; Dep | 2007 |
Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?
Topics: Adolescent; Adolescent Behavior; Adult; Analysis of Variance; Anxiety; Child; Child Behavior Disorde | 2008 |
Behavioral and neurochemical consequences of multiple MDMA administrations in the rat: role of individual differences in anxiety-related behavior.
Topics: Animals; Anxiety; Behavior, Animal; Dopamine; Drug Administration Schedule; Exploratory Behavior; Ha | 2008 |
Subjective reports on the effects of the MDMA ('ecstasy') experience in humans.
Topics: Adolescent; Adult; Anxiety; Behavior; Depression; Female; Humans; Male; N-Methyl-3,4-methylenedioxya | 1995 |
The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Diazepam; Dopamine Uptake Inhi | 1999 |
Effects of 3,4-methylenedioxy-methamphetamine (MDMA) on anxiety in mice tested in the light-dark box.
Topics: Animals; Anxiety; Disease Models, Animal; Exploratory Behavior; Hallucinogens; Light; Male; Mice; Mo | 2000 |
(+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats.
Topics: Animals; Anxiety; Cats; Electroshock; Environment; Hallucinogens; Interpersonal Relations; Male; Mot | 2000 |
Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy").
Topics: Animals; Anxiety; Body Temperature; Illicit Drugs; Male; Maze Learning; Memory Disorders; Motor Acti | 2001 |
A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field.
Topics: Animals; Anxiety; Behavior, Animal; Male; Maze Learning; Motor Activity; N-Methyl-3,4-methylenedioxy | 2002 |
Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion.
Topics: Animals; Anxiety; Body Temperature; Brain; Hallucinogens; Male; Maze Learning; Motor Activity; N-Met | 2002 |